Clinical Trial Finds That While Buprenorphine-Naloxone Maintenance Reduced Other Opioid Use Among Those Dependent on Prescription Opioids, 91% Were Not.

Slides:



Advertisements
Similar presentations
CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research February 4, 2013 Vol.
Advertisements

California Roadside Survey Finds Twice as Many Weekend Nighttime Drivers Test Positive for Other Drugs as for Alcohol; Marijuana as Likely as Alcohol CESAR.
College Students Who Use Energy Drinks More Than Twice as Likely to Initiate Nonmedical Use of Prescription Stimulants and Analgesics in Subsequent Year.
What is the evidence for time limiting addiction treatment?
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Swinomish Wellness Program
Sublingual Buprenorphine and Pain
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May-June 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2009.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
Hypermed, Inc.’s Patent-Pending Advanced Rapid Opiate Detox Protocol Stopping addiction in 8 hours without withdrawal and without relapse.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Hazelden’s Comprehensive Opioid Response and Educational Solutions Death in the Suburbs: How Prescription Painkillers and Heroin have Changed Treatment.
A secondary analysis of a study of 152 subjects aged seeking treatment for opioid dependence were randomized to 2 week detoxification with buprenorphine/naloxone.
Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.
Suboxone as an Adjunctive Medication, Not Maintenance Dennis M. Donovan, Ph.D. UW Alcohol & Drug Abuse Institute Patricia C. Knox, Ph.D. Recovery Centers.
1 Mental Health and Substance Abuse Services Division Association of Substance Abuse Providers Mike Maples October 5, 2011.
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
The NIDA Clinical Trials is conducting the Prescription Opioid Addiction Treatment Study (POATS) – a multi- site trial examining different lengths and.
Lack of Association of Cannabis Use with Opioid Outcomes among Opioid-Dependent Youth Kevin P. Hill, M.D., M.H.S. a,b, Heather E. Bennett, B.A. a, Margaret.
Using self report to gather information about drug use can be reasonably reliable and valid in certain situations, especially where there are no contingencies.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research Sales data from the.
FIVE MINUTES TO MAKE A DIFFERENCE Presentation by: Mark Barnes.
Pain Management Laura Bergs FNP. Definition of Chronic Pain Anyone with pain greater than 3 months Anyone with pain greater than 3 months Pain An unpleasant.
Medical issues about Methadone : What the counselor needs to know
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research April 29, 2013 Vol.
Study Finds Persons Who Fill Buprenorphine Prescriptions Have Higher Rates of Medical Conditions Associated with Pain and Comorbid Psychiatric Disorders.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo,
CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research March 3, 2014 Vol. 23,
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research The majority of synthetic.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research January 27, 2014 Vol.
Opiate Management Douglas Keehn DO Adjunct Assistant Clinical Professor University Wisconsin Board Certified Anesthesia & Pain Management.
Motivation Using SMART research designs to improve individualized treatments Alena Scott 1, Janet Levy 3, and Susan Murphy 1,2 Institute for Social Research.
Jennifer R. Havens, PhD, MPH Associate Professor
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
BEHAVIORAL FAMILY COUNSELING AND NALTREXONE FOR MALE OPIOID-DEPENDENT PATIENTS William Fals-Stewart, Ph.D. Research Institute on Addictions.
Opioid Treatment Basics for Counselors Thomas E. Freese, PhD Pacific Southwest Addiction Technology Transfer Center UCLA Integrated Substance Abuse Programs.
Buprenorphine {Suboxone®, Subutex®}
Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Opioid Tapering Paul Coelho, MD David Tauben, MD Melissa Weimer, DO, MCR.
CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research January 23, 2012 Vol.
Demographic Characteristics and Smoking Severity at entry into the SALOME Study Scott MacDonald 1, Eugenia Oviedo-Joekes 2,3, Kirsten Marchand 2,3, Daphne.
Opioids Tapering Melissa B. Weimer, DO, MCR. Disclosures Dr. Weimer is a consultant for INFORMed, IMPACT education, and the American Association of Addiction.
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Comparison of Contingency Management and Cognitive-Behavioral.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
Marijuana Most Commonly Detected Drug Among Male Arrestees Tested by ADAM II in Five U.S. Sites CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o.
CDC Alert: Acute Kidney Injury Associated with Synthetic Marijuana Use in Six States CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P.
Arthur Robin Williams, M.D. October 13, 2016 Medication-Assisted Treatment (MAT): Maintenance, Treatment, and Outcomes If you have any questions/comments.
Examining Potential Misuse of Gabapentin Among Patients Admitted to an Inpatient Behavioral Health Unit Samuel Kubas a, Pharm.D. Candidate 2018; Lucas.
*Risk Evaluation and Mitigation Strategy
FAX CESAR October 17, 2011 Vol. 20, Issue 39
Alcohol, Other Drugs, and Health: Current Evidence
FAX CESAR February 21, 2011 Vol. 20, Issue 7
The European Experience: Prescription Drug Misuse in France, Germany, Italy and Spain 24 October 2017 Presented at Lisbon Addictions 2017 Jody L. Green,
Maintenance Treatment
Prescription Drug Monitoring Program
Prescription Drug Monitoring Program
Presentation transcript:

Clinical Trial Finds That While Buprenorphine-Naloxone Maintenance Reduced Other Opioid Use Among Those Dependent on Prescription Opioids, 91% Were Not Opioid-Free at Follow-Up CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research December 5, 2011 Vol. 20, Issue 46 Long-term buprenorphine-naloxone treatment reduces opioid use by those dependent on prescription painkillers, according to the first randomized, controlled trial using a medication for the treatment of prescription opioid dependence. Nearly one-half (49%) of those receiving 12 weeks of treatment with the opioid buprenorphine-naloxone reduced their use of other opioids.* However, eight weeks after the buprenorphine-naloxone treatment was tapered off and discontinued in accordance with the study protocol, only 9% had reduced their opioid use. Thus 91% of the study participants were not opioid-free at follow-up. According to the authors, “The high rate of unsuccessful outcomes after buprenorphine-naloxone taper is notable in light of the good prognostic characteristics of the population (i.e., largely employed, well educated, relatively brief opioid use histories, and little other current substance abuse) and previous research suggesting that patients dependent on prescription opioids might have better outcomes than those dependent on heroin” (p. E7). The authors suggest that future research look at “what length of buprenorphine-naloxone treatment, if any, would lead to substantially better outcomes after a taper” (p. E7). [Editors Note: The findings of likely relapse after cessation of buprenorphine-naloxone treatment are not surprising to us, as buprenorphine-naloxone treatment consists primarily of replacing one opioid with another and continuing the dependence.] Percentage of Prescription Opioid-Dependent Persons Reducing Opioid Use After 12 Weeks of Buprenorphine-Naloxone Treatment and 12 Weeks of Taper/Follow-Up (N=360) SOURCE: Adapted by CESAR from Weiss, R.D., et. al., “Adjunctive Counseling During Brief and Extended Buprenorphine- Naloxone Treatment for Prescription Opioid Dependence,” Archives of General Psychiatry, Online First November 7, Available online at For more information, contact Dr. Roger Weiss at *Reduced opioid use was defined as abstaining from other opioids during the final week and during at least 2 of the previous 3 weeks of treatment or taper/follow-up. Abstinence was determined by urine test-verified self-reports; missing urine samples were considered positive for opioids. Opioids tested for included oxycodone, hydrocodone, hydromorphone, morphine, codeine, propoxyphene, and methadone.  (voice)  (fax)   CESAR FAX may be copied without permission. Please cite CESAR as the source. “Patients dependent on prescription opioids... are most likely to reduce their opioid use during the first several months of treatment while receiving buprenorphine-naloxone; if tapered off this medication, the likelihood of relapse to opioid use or dropout from treatment is overwhelmingly high” (p. E7). CESAR FAX Special Series on Buprenorphine While research indicates that buprenorphine is an effective drug for treating opioid dependence, the potential for its nonmedical use and related unintended consequences may be going unnoticed. This series of publications, available at was designed to highlight several indicators of the increased availability, diversion, and misuse of buprenorphine.